TW200626173A - IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses - Google Patents
IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and usesInfo
- Publication number
- TW200626173A TW200626173A TW094132925A TW94132925A TW200626173A TW 200626173 A TW200626173 A TW 200626173A TW 094132925 A TW094132925 A TW 094132925A TW 94132925 A TW94132925 A TW 94132925A TW 200626173 A TW200626173 A TW 200626173A
- Authority
- TW
- Taiwan
- Prior art keywords
- methods
- epitopes
- compositions
- derived proteins
- specific immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61286604P | 2004-09-24 | 2004-09-24 | |
US61683204P | 2004-10-07 | 2004-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200626173A true TW200626173A (en) | 2006-08-01 |
TWI370136B TWI370136B (en) | 2012-08-11 |
Family
ID=36119430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094132925A TWI370136B (en) | 2004-09-24 | 2005-09-23 | Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses |
Country Status (7)
Country | Link |
---|---|
US (2) | US7252971B2 (zh) |
AR (1) | AR051444A1 (zh) |
MY (1) | MY141215A (zh) |
PE (1) | PE20060694A1 (zh) |
TW (1) | TWI370136B (zh) |
UY (1) | UY29128A1 (zh) |
WO (1) | WO2006036745A2 (zh) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
WO2004042009A2 (en) * | 2002-10-30 | 2004-05-21 | Genentech, Inc. | Inhibition of il-17 production |
CA3204588A1 (en) * | 2004-12-08 | 2006-06-15 | Cedars-Sinai Medical Center | Methods for diagnosis and treatment of crohn's disease |
TR201902033T4 (tr) | 2005-06-30 | 2019-03-21 | Janssen Biotech Inc | Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları. |
US7807160B2 (en) | 2005-08-31 | 2010-10-05 | Schering Corporation | Engineered anti-IL-23 antibodies |
JP2009507023A (ja) | 2005-09-01 | 2009-02-19 | シェーリング コーポレイション | 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用 |
US10716749B2 (en) * | 2005-11-03 | 2020-07-21 | Palo Alto Investors | Methods and compositions for treating a renal disease condition in a subject |
MX2008008621A (es) | 2005-12-29 | 2008-11-27 | Centocor Inc | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos. |
US7790862B2 (en) * | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
US20100021917A1 (en) * | 2007-02-14 | 2010-01-28 | Cedars-Sinai Medical Center | Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease |
WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
NZ579297A (en) | 2007-02-28 | 2012-03-30 | Schering Corp | Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders |
US20100055700A1 (en) * | 2007-02-28 | 2010-03-04 | Cedars-Sinai Medical Center | Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease |
US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
US8486640B2 (en) | 2007-03-21 | 2013-07-16 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease |
WO2008134569A2 (en) * | 2007-04-26 | 2008-11-06 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population |
US20100144903A1 (en) * | 2007-05-04 | 2010-06-10 | Cedars-Sinai Medical Center | Methods of diagnosis and treatment of crohn's disease |
US9305137B1 (en) | 2007-05-18 | 2016-04-05 | Cedars-Sinai Medical Center | Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach |
WO2008143892A1 (en) * | 2007-05-18 | 2008-11-27 | New York University | Method of treating tuberculosis with interferons |
US9421356B2 (en) * | 2007-08-28 | 2016-08-23 | Teikoku Pharma Usa, Inc. | Transdermal methods and systems for the delivery of corticosteroid compounds |
WO2009059277A1 (en) * | 2007-11-02 | 2009-05-07 | University Of South Florida | Synergistic modulation of microglial activation by nicotine and thc |
WO2009136286A2 (en) * | 2008-05-05 | 2009-11-12 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
AU2009247782C1 (en) * | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
US20110130457A1 (en) * | 2008-08-06 | 2011-06-02 | University Of Louisville Research Foundation, Inc. | Wax-Based Emulsion for the Treatment of Dry Eye Conditions |
NZ590816A (en) * | 2008-08-14 | 2013-02-22 | Cephalon Australia Pty Ltd | Anti-il-12/il-23 antibodies |
US20110177969A1 (en) * | 2008-10-01 | 2011-07-21 | Cedars-Sinai Medical Center | The role of il17rd and the il23-1l17 pathway in crohn's disease |
US20110189685A1 (en) * | 2008-10-22 | 2011-08-04 | Cedars-Sinai Medical Center | Methods of using jak3 genetic variants to diagnose and predict crohn's disease |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
WO2010062960A2 (en) * | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
KR20170062554A (ko) * | 2008-12-18 | 2017-06-07 | 노파르티스 아게 | 1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염 |
US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
WO2010128407A2 (en) | 2009-05-05 | 2010-11-11 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
AU2010249047A1 (en) * | 2009-05-13 | 2011-11-24 | Protein Delivery Solutions, Llc | Pharmaceutical system for trans-membrane delivery |
US20110086806A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that Bind IL-23R |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
JP5730914B2 (ja) * | 2010-03-05 | 2015-06-10 | ブラス・モンキー・インコーポレイテッドBrass Monkey,Inc. | Webブラウザにおける双方向通信および内容制御のシステムおよび方法 |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
MX341309B (es) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anticuerpos especificos del heterodimero de anti-il-23. |
SG194710A1 (en) | 2011-05-10 | 2013-12-30 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
WO2014113068A1 (en) * | 2013-01-18 | 2014-07-24 | Loma Linda University | Compositions and methods for diagnosing and treating sepsis |
CN105246501B (zh) | 2013-03-27 | 2021-01-12 | 雪松-西奈医学中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112232A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device |
JP2020523560A (ja) | 2017-05-31 | 2020-08-06 | プロメテウス バイオサイエンシーズ インコーポレイテッド | クローン病患者の粘膜治癒を評価する方法 |
EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
WO1999040195A1 (en) | 1998-02-06 | 1999-08-12 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
ATE474849T1 (de) | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
WO2000009552A1 (en) | 1998-08-14 | 2000-02-24 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US6800460B1 (en) | 1999-03-11 | 2004-10-05 | Schering Corporation | Mammalian cytokine complexes |
ES2319958T3 (es) | 1999-03-11 | 2009-05-18 | Schering Corporation | Citoquinas de mamifero: reactivos y procedimientos asociados. |
EP1179066A2 (en) | 1999-05-19 | 2002-02-13 | Incyte Genomics, Inc. | Extracellular signaling molecules |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
JP4505166B2 (ja) | 1999-09-09 | 2010-07-21 | シェーリング コーポレイション | 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用 |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
SK287984B6 (sk) | 2000-05-10 | 2012-08-06 | Schering Corporation | Substantially pure or recombinant polypeptide, nucleic acid, host cell, method for the preparation of polypeptide, binding compound, kit, composition comprising an antibody and use thereof |
MXPA05000476A (es) * | 2002-07-17 | 2005-03-23 | Warner Lambert Co | Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
WO2004042009A2 (en) | 2002-10-30 | 2004-05-21 | Genentech, Inc. | Inhibition of il-17 production |
ES2367302T3 (es) | 2002-12-23 | 2011-11-02 | Schering Corporation | Usos de la citoquina il-23 de mamífero; reactivos relacionados. |
WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
DK1601694T3 (da) | 2003-03-10 | 2009-12-14 | Schering Corp | Anvendelser af IL23-antagonister, relaterede reagenser |
JP2007535930A (ja) | 2004-05-03 | 2007-12-13 | シェーリング コーポレイション | 皮膚の炎症を予測するためのil−17発現の使用;処置方法 |
-
2005
- 2005-09-20 AR ARP050103931A patent/AR051444A1/es unknown
- 2005-09-22 MY MYPI20054459A patent/MY141215A/en unknown
- 2005-09-22 PE PE2005001099A patent/PE20060694A1/es not_active Application Discontinuation
- 2005-09-23 US US11/234,011 patent/US7252971B2/en active Active
- 2005-09-23 UY UY29128A patent/UY29128A1/es unknown
- 2005-09-23 WO PCT/US2005/034000 patent/WO2006036745A2/en active Application Filing
- 2005-09-23 TW TW094132925A patent/TWI370136B/zh not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/768,582 patent/US7807471B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US7252971B2 (en) | 2007-08-07 |
WO2006036745A2 (en) | 2006-04-06 |
MY141215A (en) | 2010-03-31 |
PE20060694A1 (es) | 2006-09-01 |
US20060067936A1 (en) | 2006-03-30 |
US7807471B2 (en) | 2010-10-05 |
WO2006036745A3 (en) | 2006-12-28 |
AR051444A1 (es) | 2007-01-17 |
UY29128A1 (es) | 2005-11-30 |
TWI370136B (en) | 2012-08-11 |
US20080038831A1 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200626173A (en) | IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses | |
NZ577828A (en) | Human antibodies that bind human il-12 and methods for producing | |
CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
TW200716745A (en) | Anti-TNF antibodies, compositions, methods and uses | |
WO2004101750A3 (en) | IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | |
WO2004003147A3 (en) | Cngh0004 polypeptides, antibodies, compositions, methods and uses | |
WO2006085961A3 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
HK1118458A1 (en) | Anti-il-23 antibodies, compositions, methods and uses | |
JO3058B1 (ar) | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها | |
WO2005005604A3 (en) | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses | |
TW200716174A (en) | Anti-MCP-1 antibodies, compositions, methods and uses | |
WO2003086451A8 (en) | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses | |
WO2005028511A3 (en) | Anti-amyloid antibodies, compositions, methods and uses | |
MY133377A (en) | Anti-il-12 antibodies, compositions, methods and uses | |
MX2010004179A (es) | Anticuerpos anti-amiloide, composiciones, metodos y usos. | |
WO2006124451A3 (en) | Anti-il-13 antibodies, compositions, methods and uses | |
WO2003047510A3 (en) | Anti-tnf antibodies, compositions, methods and uses | |
TW200508246A (en) | Anti-dengue virus antibodies, compositions, methods and uses | |
WO2003038041A3 (en) | Il-4 mutein proteins, antibodies, compositions, methods and uses | |
WO2003102017A3 (en) | Anti-relp fusion antibodies, compositions, methods and uses | |
WO2003057821A3 (en) | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses | |
WO2003082206A3 (en) | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses | |
WO2003083059A3 (en) | Mcp-1 mutant proteins, antibodies, compositions, methods and uses | |
WO2008048871A3 (en) | Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |